BRIEF-ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial

Reuters
19 Nov 2024
Binah Capital Group Inc0.00%Post-market

Nov 19 (Reuters) - Immunitybio Inc :

* IMMUNITYBIO COMPLETES ANKTIVA’S POST-APPROVAL ENROLLMENT OF THE 100TH PATIENT IN BCG UNRESPONSIVE NMIBC CIS TRIAL AND REPORTS A COMPLETE RESPONSE RATE OF 71% WITH A DURABLE DURATION OF RESPONSE RANGING UP TO 54 MONTHS

* IMMUNITYBIO INC - DATA TO BE SUBMITTED TO EMA IN Q4 2024

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."